Does the LDLR rs688 variant raise LDL cholesterol by altering receptor splicing?

The LDLR rs688 variant is a well-characterized genetic polymorphism that directly impacts cholesterol metabolism by altering the splicing efficiency of the Low-Density Lipoprotein Receptor (LDLR) gene. This variant, located in exon 12, serves as a critical model for how synonymous mutations—which do not change the amino acid sequence—can still significantly influence disease risk by disrupting regulatory mechanisms.

Mechanistic evidence

The rs688 variant (c.1706C>T) functions by disrupting an exonic splicing enhancer (ESE) sequence.

• Alternative Splicing: Molecular studies, including minigene assays and analysis of human liver tissue, demonstrate that the presence of the "T" allele leads to increased skipping of exon 12 during pre-mRNA processing.
• Protein Expression: This splicing error results in truncated or unstable mRNA transcripts, which reduces the total amount of functional LDLR protein reaching the cell surface by approximately 10% to 20%.
• Receptor Function: Because exon 12 is part of the β-propeller domain essential for ligand binding and pH-dependent receptor recycling, its absence or alteration impairs the receptor's ability to bind, internalize, and clear LDL particles from the bloodstream.

Clinical and effectiveness evidence

The reduction in functional receptors translates into measurable differences in lipid profiles across diverse populations.

• LDL Elevation: Large-scale association studies, including the Framingham Heart Study and various meta-analyses, consistently link the rs688 "T" allele with significantly higher total and LDL cholesterol (LDL-C) levels.
• Dose-Response Effect: Evidence suggests a dose-response relationship, where individuals carrying two copies of the "T" allele (homozygotes) exhibit the highest LDL-C concentrations compared to those with the "CC" genotype.
• Cardiovascular Risk: Due to the sustained elevation of circulating LDL particles, carriers of the variant allele face a heightened risk for coronary artery disease (CAD), with some studies reporting increased odds ratios for cardiovascular events in both male and female cohorts.

Bottom line

The LDLR rs688 variant is a confirmed genetic factor that reduces the efficiency of LDL receptor splicing. This molecular defect leads to fewer functional receptors on the liver surface, reduced clearance of LDL particles, and a subsequent increase in plasma LDL cholesterol, contributing to an elevated risk of cardiovascular disease.